Altimmune (NASDAQ:ALT) Trading Down 2.7%

Shares of Altimmune, Inc. (NASDAQ:ALTGet Free Report) dropped 2.7% during mid-day trading on Wednesday . The stock traded as low as $7.15 and last traded at $7.18. Approximately 196,126 shares were traded during trading, a decline of 96% from the average daily volume of 4,678,175 shares. The stock had previously closed at $7.38.

Analyst Ratings Changes

ALT has been the subject of several analyst reports. Guggenheim downgraded shares of Altimmune from a “buy” rating to a “neutral” rating in a research note on Monday, April 29th. JMP Securities dropped their price target on shares of Altimmune from $25.00 to $24.00 and set a “market outperform” rating for the company in a research note on Friday, May 10th. B. Riley reaffirmed a “buy” rating and set a $20.00 price target on shares of Altimmune in a research note on Thursday, March 28th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Altimmune in a research note on Tuesday, May 14th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $17.25.

Check Out Our Latest Stock Analysis on Altimmune

Altimmune Stock Down 1.2 %

The business’s 50 day moving average is $7.82 and its two-hundred day moving average is $8.53. The firm has a market cap of $516.86 million, a P/E ratio of -4.41 and a beta of 0.11.

Altimmune (NASDAQ:ALTGet Free Report) last announced its earnings results on Thursday, May 9th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.02. Altimmune had a negative net margin of 22,645.37% and a negative return on equity of 46.96%. The business had revenue of $0.01 million during the quarter. During the same period in the prior year, the business earned ($0.40) EPS. Equities research analysts anticipate that Altimmune, Inc. will post -1.34 EPS for the current year.

Institutional Investors Weigh In On Altimmune

A number of large investors have recently bought and sold shares of the stock. North Star Investment Management Corp. bought a new stake in Altimmune in the first quarter worth about $31,000. FNY Investment Advisers LLC bought a new stake in Altimmune in the fourth quarter worth about $35,000. Russell Investments Group Ltd. raised its position in Altimmune by 1,150.9% in the fourth quarter. Russell Investments Group Ltd. now owns 4,303 shares of the company’s stock worth $48,000 after acquiring an additional 3,959 shares during the period. CANADA LIFE ASSURANCE Co bought a new stake in Altimmune in the first quarter worth about $44,000. Finally, TFO Wealth Partners LLC bought a new stake in Altimmune in the first quarter worth about $51,000. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Altimmune Company Profile

(Get Free Report)

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.

Featured Articles

Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.